Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIVV001 (efanesoctocog alfa) in severe hemophilia A
NCT04161495Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2019
- Primary completion
- Feb 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 19
01
Overview
Phase 3, open-label trial of efanesoctocog alfa in hemophilia A (2 arms), sponsored by Sanofi. Primary endpoints: Estimated Annualized Bleeding Rate at 52 weeks and Observed Annualized Bleeding Rate at 52 weeks. Started Nov 2019; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04161495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161495.